Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Significance: Cancer suppressor p53 is mutated in more than 50% of different human cancers. This study suggests a therapeutic strategy as to how mutant p53 expressing human cancers can be cured by activating its “unmutated homologous proteins”, such as TAp63. Roquin, by down regulation of its target gene, it may increase the expression of tumor suppressor TA-p63. Thereby, it may promote tumor suppression. Together, this study suggests a therapeutic strategy as to how one can cure cancer, by activating an alternative unmutated cancer suppressor, with Roquin activators. Thus, pharmacological formulations encompassing “Roquin activators” can be used to inhibit the progression of human tumors, including p53-mutated human tumors.
To cite: Boominathan, Molecular therapy for p53-mutated Human Cancers: Roquin [RING finger and CCCH-type zinc finger domain-containing protein 1] increases the expression of tumor suppresor TA-p63 via down regulation of its target gene, 18/March/2015, 8.14 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation
Undisclosed information: How Roquin increases the expression of TA-p63